5 Bad Habits The Clinical Trial Community Needs To Break ASAP

OccamPoint located in Burlington, CA

The issue of clinical trial costs, both in terms of money and time, is big, complicated, and not at all new. The article discusses key persistent root causes and calls to arms to implement 21st century mindset in the execution of clinical trials.


Share On:

1 Comment

  1. Alethea Wieland on July 7, 2020 at 8:57 pm

    Dean Gittleman’s article highlights well-known issues that drag clinical research down. He especially identifies problems in clinical monitoring and source data verification (SDV) that have been proven to be replaceable with more automation and virtual monitoring. Further, I have experienced first-hand how risk-based monitoring (RBM) has been used to wreck havoc on trials because so few people in third-party partner CROs understand how to optimize trial designs and endpoint analyses along with the associated risks at their most basic levels. Additionally, people cling to old habits in trials which have become over-processed with unnecessary costs, like on-site clinical monitoring and 100% SDV, that Dean’s article correctly points out. It’s time to put bad practices to rest.

Leave a Comment